Fibroblast growth factor 21 variants

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 8883726
APP PUB NO 20130324460A1
SERIAL NO

13965243

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

This present invention relates to pharmacologically potent and/or stable variants of human fibroblast growth factor 21 (FGF21), pharmaceutical compositions comprising FGF21 variants, and methods for treating type 2 diabetes, obesity, dyslipidemia, or metabolic syndrome, or any combination thereof, using such variants.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • ELI LILLY AND COMPANY

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Darling, Ryan James Fishers, US 11 340
Dickinson, Craig Duane San Diego, US 15 290
Driver, David Albert Solana Beach, US 7 150
Gonciarz, Malgorzata Donata Indianapolis, US 7 120
Micanovic, Radmila Indianapolis, US 16 1078

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 May 11, 2026
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00